Biotech2050’s Post

Join Rahul Chaturvedi for a conversation with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder & President, of PureTech Health, on a new episode of Biotech2050. Bharatt and Eric dive deep into PureTech’s R&D model—one that prioritizes solving specific problems over traditional approaches. They share their professional journeys, emphasizing the power of simplicity, persistence, and patient-centered innovation. The discussion includes a look at the rise of Karuna Therapeutics, a PureTech-founded company, and its journey to developing a transformative schizophrenia treatment. Tune in for valuable insights into the future of drug development, the need for more efficient pathways, and an exciting glimpse at what’s next for PureTech. #Clora #biotech #podcast #drugdevelopment #innovation #schizophrenia

"There is a better way for large pharma to support innovation" - Stella K. Vnook, CEO Likarda This is so interesting! Stella K. Vnook shares her fascinating perspective on the relationship between big pharma and small biotech. She highlights what each can learn from the other and how a change in mindset could unlock tremendous value. Stay tuned for the full episode 9 release tomorrow! The BioHub Podcast🚀 #TheBioHub #Podcast #Biotech #Innovation #Pharma #SmallBiotech #StellaVnook #Collaboration #Healthcare #FutureOfMedicine

2,500 #Subscribers is worth a make-over🎉 ➡https://lnkd.in/gdJqZ_Hm #Pharma #MedTech, #BioTech, #MedicalDevice & #Healthcare colleagues, tell me what topics (or Guests) would you like to see on Amplifiz #Podcast? In our next 2 episodes: 🔜 I pick the brain of an E-Commerce Leader in Pharma on how to reimagine the Industry value-chain. 🔜 I ask a Marketing Leader for a large Healthcare Group about Patients centricity and how to concretely improve CX & CSAT. 🔜 More to come (CEO in MedTech...).

Over the last 20 years CDMOS have changed They are redefining their role in Pharma! CDMOs are no longer just vendors. They are collaborative partners driving innovation in the drug development process. On the latest podcast episode I chat with Sarah Stevens. She discusses how Azzur Group's technology "Clean Rooms on Demand" is an example of this shift towards more strategic, partnership-driven roles. To learn more, Click here 👉🏼 https://lnkd.in/dcaJy-zQ Have you worked with any companies that act more like partners than just vendors? Would love to hear your experiences!

💼 Why Has Biopharma M&A Slowed in 2024? 💊 Despite entering 2024 with what seemed like prime conditions for biopharma dealmaking, M&A activity in the sector took a noticeable dip during Q2 and Q3—both in deal volume and total value. So, what happened? In the latest Scrip M&A Podcast, senior writer Joseph Haas dives into this trend with insights from Gerardo Ubaghs (CFO, Frontier Medicines) and Jason Silvers (CFO, Generate Biomedicines). Both bring deep expertise, having transitioned from investment banking to leadership roles in biotech. 🧠 Key Topics Discussed: 🔹 Factors contributing to the slowdown in M&A activity 🔹 Predictions for a potential rebound 🔹 How the 2024 US presidential election might shape biopharma dealmaking If you’re keeping an eye on the shifting dynamics of biopharma M&A, this is a must-listen. 🎧 Check out the podcast and join the conversation on what’s next for biopharma dealmaking! #Biopharma #MergersAndAcquisitions #HealthcareBusiness #Podcast #Citeline #M&A #Q3

Here is a Soundcloud link to the latest edition of the Scrip M&A Podcast, on which I am joined by a pair of CFOs, Gerardo Ubaghs of Frontier Medicines and Jason Silvers of Generate Biomedicines to discuss trends in biopharma M&A. Topics include why M&A metrics decline in Q2 and Q3 and what impact the US election may have on dealmaking. https://lnkd.in/e-eWRQKw

Excited to announce the release of Episode 23 of BioTalk Unzipped! 🎙️   In this second half of our fascinating conversation with Scott Ogle, CEO of TruLab, Real-Time Technology for Clinical Trial Oversight, Dr. Chad Briscoe and I dive into key trends shaping the biotech industry and beyond. 🌐💡   💼 We explore surprising parallels between the banking and pharma industries, the game-changing role of digital twinning in clinical trials, and the evolving landscape of biotech funding.   Scott also shares personal insights on leadership, mentorship, and the impact of the Inflation Reduction Act on pharma innovation.   This episode is packed with valuable takeaways for anyone navigating the world of biotech and drug development.   🔍 Topics include:   ✔️Biotech funding and macroeconomic factors ✔️How AI-powered digital twinning could revolutionize clinical trials ✔️The importance of maintaining data integrity in decentralized trials ✔️The influence of family and mentorship on leadership   Scott is a very engaging and genuine guy whom I think you'll enjoy.   Don't miss this episode filled with practical advice, bold insights, and a fresh perspective on innovation in pharma!   🎧 The Episode: https://lnkd.in/gUg3EZfV   #BioTalkUnzipped #Biotech #PharmaInnovation #ClinicalTrials #Leadership #Mentorship #BiotechFunding #Podcast

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan Sarac, and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: #Biotech #TrialDesign #ClinicalDevelopment

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan B. Sarac (MD, MSc, PhD), and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: https://lnkd.in/g9Kt5hGA #Biotech #TrialDesign #ClinicalDevelopment

How does a biotech company coordinate clinical trials across multiple continents? Listen to our latest episode with Akeem Gardner to find out! Akeem is the CEO of Canurta, a Canadian-based biotech company that specializes in extracting and enriching rare molecules found in nature and developing them into botanical therapeutics to help patients who are suffering from major neurodegenerative and inflammatory diseases. In this episode, he shares practical tips on leveraging government resources and managing international teams. We also discuss the lessons he has learned along the way, networking, languages, and bridging cultural gaps. Hear this episode at: https://hubs.ly/Q02YR12t0 And follow the Global Marketing Show on our site or your favorite podcast platform, so you never miss an episode #GlobalHealth #Innovation #BiotechStartup #InternationalBusiness